search
Back to results

CKD-330 Phase 3 Trial in Amlodipine Non-responder

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-330 16/5mg
Amlodipine 5mg Placebo
CKD-330 16/5mg Placebo
Amlodipine 5mg
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of 19 or above
  • Essential hypertension with 140mmHg ≤ mean sitSBP < 180mmHg on target arm at Visit 2
  • Ability to provide written informed consent

Exclusion Criteria:

  • The difference between arms of sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg at Visit 1
  • mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 1
  • mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 2
  • Known or suspected Secondary Hypertension
  • Type I Diabetes Mellitus and Type II Diabetes Mellitus with HbA1c > 9%
  • Patients with severe congestive heart failure(NYHA class III, IV)
  • Patient with ischemic heart disease, Ischemic cardiovascular disease, Valvular heart disease, arrhythmia requiring treatment within 3 months
  • History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
  • History of severe or malignant retinopathy
  • AST/ALT ≥ UNL*3, Serum creatinine ≥ UNL*1.5, K > 5.5mEq/L
  • Patients with acute or chronic inflammatory status requiring treatment
  • Patient who need to take antihypertensive drug besides Investigational products
  • Patient must be treated with medications prohibited for concomitant use during the study period
  • History of angioedema related to ACE inhibitor or angiotensin II receptor blockers
  • History of disability to drug ADME, active inflammatory bowel syndrome within 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract
  • History of malignant tumor within 5 years
  • Patient who are dependent on drugs or alcohol within 6 months
  • Hypersensitive to Candesartan/Amlodipine
  • Women with pregnant, breast-feeding
  • Patients treated with other investigational product within 30 days at first time taking the investigational product
  • Not eligible to participate for the study at the discretion of investigator

Sites / Locations

  • Korea University Guro Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CKD-330 16/5mg + Amlodipine 5mg placebo

CKD-330 16/5mg placebo + Amlodipine 5mg

Arm Description

CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.

CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.

Outcomes

Primary Outcome Measures

The mean change of sitSBP(sitting Systolic blood pressure)

Secondary Outcome Measures

The mean change of sitSBP(sitting Systolic blood pressure)
The mean change of sitDBP(sitting diastolic blood pressure)
Blood Pressure Control rate
Patient achieving sitSBP < 140mmHg and sitDBP < 90mmHg
Blood Pressure Response rate
sitSBP reduction ≥ 20mmHg and sitDBP reduction ≥ 10mmHg

Full Information

First Posted
October 23, 2015
Last Updated
October 4, 2016
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT02586311
Brief Title
CKD-330 Phase 3 Trial in Amlodipine Non-responder
Official Title
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2016 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy
Detailed Description
A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
160 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CKD-330 16/5mg + Amlodipine 5mg placebo
Arm Type
Experimental
Arm Description
CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
Arm Title
CKD-330 16/5mg placebo + Amlodipine 5mg
Arm Type
Active Comparator
Arm Description
CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
Intervention Type
Drug
Intervention Name(s)
CKD-330 16/5mg
Intervention Description
Once a day, 8 weeks
Intervention Type
Drug
Intervention Name(s)
Amlodipine 5mg Placebo
Other Intervention Name(s)
Norvasc 5mg Placebo
Intervention Description
Once a day, 8 weeks
Intervention Type
Drug
Intervention Name(s)
CKD-330 16/5mg Placebo
Intervention Description
Once a day, 8 weeks
Intervention Type
Drug
Intervention Name(s)
Amlodipine 5mg
Other Intervention Name(s)
Norvasc 5mg
Intervention Description
Once a day, 8 weeks
Primary Outcome Measure Information:
Title
The mean change of sitSBP(sitting Systolic blood pressure)
Time Frame
From baseline at week 8
Secondary Outcome Measure Information:
Title
The mean change of sitSBP(sitting Systolic blood pressure)
Time Frame
From baseline at week 4
Title
The mean change of sitDBP(sitting diastolic blood pressure)
Time Frame
From baseline at week 4 and week 8
Title
Blood Pressure Control rate
Description
Patient achieving sitSBP < 140mmHg and sitDBP < 90mmHg
Time Frame
From baseline to week 8
Title
Blood Pressure Response rate
Description
sitSBP reduction ≥ 20mmHg and sitDBP reduction ≥ 10mmHg
Time Frame
From baseline to week 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of 19 or above Essential hypertension with 140mmHg ≤ mean sitSBP < 180mmHg on target arm at Visit 2 Ability to provide written informed consent Exclusion Criteria: The difference between arms of sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg at Visit 1 mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 1 mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg on target arm at Visit 2 Known or suspected Secondary Hypertension Type I Diabetes Mellitus and Type II Diabetes Mellitus with HbA1c > 9% Patients with severe congestive heart failure(NYHA class III, IV) Patient with ischemic heart disease, Ischemic cardiovascular disease, Valvular heart disease, arrhythmia requiring treatment within 3 months History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months History of severe or malignant retinopathy AST/ALT ≥ UNL*3, Serum creatinine ≥ UNL*1.5, K > 5.5mEq/L Patients with acute or chronic inflammatory status requiring treatment Patient who need to take antihypertensive drug besides Investigational products Patient must be treated with medications prohibited for concomitant use during the study period History of angioedema related to ACE inhibitor or angiotensin II receptor blockers History of disability to drug ADME, active inflammatory bowel syndrome within 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract History of malignant tumor within 5 years Patient who are dependent on drugs or alcohol within 6 months Hypersensitive to Candesartan/Amlodipine Women with pregnant, breast-feeding Patients treated with other investigational product within 30 days at first time taking the investigational product Not eligible to participate for the study at the discretion of investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chang Gyu Park, M.D, Ph.D
Organizational Affiliation
Korea University Guro Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Korea University Guro Hospital
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CKD-330 Phase 3 Trial in Amlodipine Non-responder

We'll reach out to this number within 24 hrs